Evidence supporting the use of: Lactobacillus brevis
For the body system: GABA

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Lactobacillus brevis is a probiotic bacterium that has gained attention for its potential to modulate the gamma-aminobutyric acid (GABA) system in the body. GABA is the primary inhibitory neurotransmitter in the central nervous system, and its modulation is linked to effects on mood, anxiety, and stress. Some strains of L. brevis, notably L. brevis DPC6108 and L. brevis FPA3709, have demonstrated the ability to produce GABA in vitro through the decarboxylation of glutamate. Animal studies have shown that administration of GABA-producing probiotics can influence GABA receptor expression and may have anxiolytic effects. However, direct evidence from human clinical trials specifically assessing L. brevis supplementation for GABA-related outcomes is limited and largely preliminary.

The majority of scientific validation is based on laboratory and animal models, indicating a possible mechanism by which L. brevis could support the GABA system. There is also interest in using fermented foods containing L. brevis as a dietary source of GABA. However, robust clinical trials in humans are lacking, and the overall strength of evidence is moderate to low at this time. Therefore, while the use of L. brevis to support the GABA system is grounded in plausible science, more research is needed to confirm its efficacy and relevance in human health.

More about lactobacillus brevis
More about GABA